Recent clinical data (1) suggest that c-erbB-2 overexpression/amplification might be associated with tamoxifen resistance in patients with estrogen receptor (ER)-positive tumors. This association is controversial, however, and the question of the efficacy of hormone therapy in these patients is still a matter of debate. In a recent issue of the Journal, Konecny et al. (2) provided some answers to this question. After considering c-erbB-2, ER, and progesterone receptors (PRs) as continuous variables, they reported that patients with higher levels of c-erbB-2 overexpression had statistically significantly lower ER and PR levels than patients with lower levels of c-erbB-2 overexpression. They suggested that this finding might explain the relative resistance of c-erbB-2-positive, hormone receptor-positive tumors to hormone therapy.
Given the small number of retrospective studies offering data relevant to this question, we strictly reproduced the methodology of Konecny et al. (2) in a retrospective series of 488 patients with primary breast cancer and a median follow-up of 10 years for whom c-erbB-2, ER, and PR expression had been measured by quantitative biochemical methods, allowing them to be analyzed as continuous variables. The patients' characteristics have been published elsewhere (3) . For this analysis, 101 (20.7%) of the 488 patients were considered to be c-erbB-2-positive (protein levels above 350 IU/mg protein), providing separation of patients with regard to diseasefree survival (P ‫ס‬ .002) and overall survival (P<.001). This c-erbB-2 positivity frequency is in the range of published values (2, 4) .
Our results were as follows. First, among patients with c-erbB-2-overexpressing tumors (n ‫ס‬ 101), we found a negative correlation between c-erbB-2 and ER and PR levels (ER: r ‫ס‬ -0.41, P<.001; PR: r ‫ס‬ -0.24, P ‫ס‬ .01). Second, patients with c-erbB-2-positive tumors had statistically significantly lower absolute ER and PR levels than patients whose tumors did not overexpress c-erbB-2 (Table 1) . Third, when we divided the 101 patients with c-erbB-2-positive tumors into two subgroups of approximately equal size, the median ER level was statistically significantly lower in the 52 patients with higher c-erbB-2 overexpression than in the 49 patients with weaker c-erbB-2 overexpression. Fourth, when we restricted this analysis to patients with hormone receptor-positive tumors (Table 1) , those with higher c-erbB-2 overexpression had a lower median ER level than those with lower c-erbB-2 overexpression. Differences in PR levels were not statistically significant.
Thus, by applying the methodology of Konecny et al. retrospectively to an independent population, we confirmed their results, i.e., the higher the level of c-erbB-2 overexpression, the lower the ER level, both in the overall population and in the subset of patients with hormone receptor-positive tumors. Because the response to endocrine therapy depends on ER and PR levels, not only on arbitrarily defined ER and PR status (positive versus negative), the lower ER and PR expression in c-erbB-2-positive/ ER-positive tumors could explain the failure of this treatment in such patients. Indeed, there is compelling evidence that cross-talk between ER and growth factor receptor pathways, such as those involving the EGFR/c-erbB-2 family, can alter ER function and thereby contribute to tumor growth and tamoxifen resistance (5-7). Taken together, these results emphasize the importance of considering the quantitative levels of c-erbB-2 and ER rather than using dichotomous systems. 
RESPONSE
The role of HER-2/neu in influencing steroid hormone receptor status is an area of some controversy. Spyratos et al. have confirmed our findings using a large cohort of primary breast cancer patients and different antibodies than we used for the quantitative measurement of HER-2/neu expression. This confirmatory study strengthens the conclusion that HER-2/neu amplification/overexpression is associated with lower tumor estrogen and progesterone receptor levels, even in those patients otherwise classified as hormone receptor-positive. These data add to the growing body of biologic and molecular evidence of critical cross-talk between the HER-2/neu and steroid hormone receptor pathways (1) . More important, such data have substantial clinical therapeutic implications because response to tamoxifen therapy is closely associated with the absolute levels of estrogen or progesterone receptor expression.
Our results and those of Spyratos et al. provide a possible explanation for the reduced response to tamoxifen in women with hormone receptor-positive tumors containing HER-2/neu amplification/overexpression. Furthermore, the data argue against the interpretation of the results of two recently published retrospective studies whose authors have proposed that estrogen withdrawal, whether by treatment with aromatase inhibitors (such as letrozole) in postmenopausal patients (2) or by oophorectomy in premenopausal breast cancer patients (3), might be the preferred treatment choice for women with hormone receptor-positive tumors containing HER-2/ neu amplification/overexpression. In the first study, postmenopausal women with hormone receptor-positive primary breast cancer were randomly assigned to receive preoperative letrozole or tamoxifen (2). Overall, there was a higher response to letrozole than to tamoxifen, but the difference was statistically significant only in the pooled subpopulation of patients with tumors classified as EGFR-or HER-2/neu-positive, and not in those patients with EGFR-and HER-2/neu-negative tumors. In the second study, premenopausal women with estrogen receptor-positive, operable breast cancer were randomly assigned to receive adjuvant surgical oophorectomy and tamoxifen daily for 5 years or to observation. Adjuvant endocrine therapy was superior to observation in terms of disease-free and overall survival, but women with HER-2/neu-overexpressing tumors were more likely to benefit from endocrine therapy than those with HER-2/neu non-overexpressing tumors.
Although these two studies appear to indicate that women with hormone receptor-positive tumors containing HER-2/neu amplification/overexpression are likely to benefit from estrogen withdrawal therapy, both studies had shortcomings in that they were retrospective studies performed in small cohorts. (The studies included only 36 EGFR/HER-2/ neu-and 73 HER-2/neu-positive patients, respectively, and in the latter study, only 27 HER-2/neu-positive patients received the endocrine therapy, and even fewer events were reported.) Thus, the data from both studies are not sufficiently robust to allow us to conclude that HER-2/neu measurements can be used to select an aromatase inhibitor or oophorectomy as the preferred treatment for women with hormone receptor-positive tumors containing HER-2/neu amplification/overexpression. Furthermore, the reduced expression of the hormone receptors in tumors containing HER-2/neu amplification/overexpression makes it unlikely that estrogen ablation will be substantially more active than tamoxifen in HER-2/neupositive breast cancer. Finally, a recent large retrospective study (4) in 562 patients (164 HER-2/neu-positive) with metastatic breast cancer showed that patients with HER-2/neu-positive tumors had a lower response to both tamoxifen and letrozole than patients with HER-2/ neu-negative tumors. The findings of this study are precisely what would be predicted from the quantitative inverse relationship between HER-2/neu and estrogen receptor expression presented by our group and now confirmed by Spyratos et al. Additional retrospective analyses of sufficiently powered studies with patients who are correctly analyzed for the quantitative levels of HER-2/neu gene amplification and hormone receptor expression will be necessary to fully characterize the predictive value of hormone receptor levels in women with hormone receptor-positive tumors containing HER-2/neu amplification/overexpression.
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